Mineralys Therapeutics, Inc. MLYS Accrued Liabilities, Current
Accrued Liabilities, Current at other companies
Other financials
Where this comes from
Reported directly by Mineralys Therapeutics, Inc. in its filing.
Tagged under the XBRL concept us-gaap:AccruedLiabilitiesCurrent.
The official record: Mineralys Therapeutics, Inc.’s 10-Q, filed May 6, 2026, on SEC EDGAR. View the filing →
Ask your AI about Mineralys Therapeutics, Inc.'s accrued liabilities, current.
Connect your AI assistant and compare it to peers, right in your chat.
Connect your AI
Claude
Questions, answered.
- What is Mineralys Therapeutics, Inc.'s accrued liabilities, current?
- Mineralys Therapeutics, Inc. (MLYS) reported accrued liabilities, current of $13.6M in Q1 2026.
- How has Mineralys Therapeutics, Inc.'s accrued liabilities, current changed year-over-year?
- Mineralys Therapeutics, Inc.'s accrued liabilities, current increased by 4.5% year-over-year, from $13.01M to $13.6M.
- What is the long-term trend for Mineralys Therapeutics, Inc.'s accrued liabilities, current?
- Over 3 years (2022 to 2025), Mineralys Therapeutics, Inc.'s accrued liabilities, current has grown at a 28.6% compound annual growth rate (CAGR), from $6.16M to $13.1M.